𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Inflammatory breast cancer treated with surgery, chemotherapy and allogeneic tumor cell/BCG immunotherapy

✍ Scribed by Charles Wiseman; J. M. Jessup; Terry L. Smith; Evan Hersh; James Bowen; George Blumenshein

Publisher
John Wiley and Sons
Year
1982
Tongue
English
Weight
477 KB
Volume
49
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Controlled clinical trial of adjuvant im
Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer
✍ B. N. Gray; C. Walker; L. Andrewartha; S. Freeman; R. C. Bennett πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 342 KB

A controlled, randomised clinical trial of immunotherapy was performed in 301 patients with stage B or C colorectal cancer. The immunotherapy treatment consisted of 18 vaccinations over a 2 year period following surgery with a combination of BCG given by scarification plus subcutaneous injection of

Monitoring of disseminated tumor cells i
Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
✍ Vilde Drageset; Jahn M. Nesland; Bjorn Erikstein; Eva Skovlund; Hilde Sommer; Gu πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 French βš– 139 KB πŸ‘ 1 views

## Abstract The present study aimed to investigate the clinical relevance of disseminated tumor cells (DTC) in breast cancer patients before and after high‐dose adjuvant chemotherapy with or without progenitor stem‐cell support. One hundred and eighteen high‐risk stage II breast cancer patients ent

Outcomes of patients with stage III nons
Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery
✍ Hale B. Caglar; Elizabeth H. Baldini; Megan Othus; Michael S. Rabin; Raphael Bue πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 177 KB πŸ‘ 2 views

## Abstract ## BACKGROUND: The objective of this study was to identify the factors associated with improved outcome after treatment for stage III nonsmall cell lung cancer (NSCLC). ## METHODS: A retrospective review of stage III NSCLC patients treated at who were treated at the Dana‐Farber Cance